End of the day, moving on from Remi and his bride was the right thing to do.
Either simufilam works and they'll need a leader who can negotiate the sale of the biz -- or it won't, at which point there's not a lot of reason for Cassava to to exist.
In the former case, I wouldn't trust Remi to get it right. In the latter case, it probably won't matter who the CEO is, the share price will be $1, give or take.
its striking how many similarities there are to IMMU -- the husband and wife leadership forced out. Complete dependency on 1 drug. Each having their own fiasco. In IMMU's case, the drug worked and the only thing which mattered was having the right team to get a deal done.
For me, if simufilam works, even modestly, and the side effects are minimal (an enormous advantage), the drug is worth $20-40 Billion. 40-80x where it is now. This is priced for a 5% chance of success. I like those odds. With Remi gone, the odds of getting a favorable deal go up a lot.
All this said, my 'bet' on SAVA is tiny. I'm not going to lose ANY sleep on this. |
